Search results
Results from the WOW.Com Content Network
The discovery of the TIBO compounds led to the definition of the NNRTI class in the late 1980s [2] when they were unexpectedly found to inhibit RT. This finding initiated researches on mechanism of action for these compounds. The HEPT compounds were described before the TIBO compounds and were originally believed to be NRTIs.
A second mechanism is the disruption of important interactions on the inside of the pocket. For example, Y181C and Y188L result in the loss of important aromatic rings involved in NNRTI binding. [20] [21] The third type of mutations result in changes in the overall conformation or the size of the NNRTI binding pocket. An example is G190E, which ...
Rilpivirine, sold under the brand name Edurant among others, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. [6] [7] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.
Emtricitabine (commonly called FTC, systematic name 2',3'-dideoxy-5-fluoro-3'-thiacytidine [2]), with trade name Emtriva (formerly Coviracil), is a nucleoside reverse-transcriptase inhibitor (NRTI) for the prevention and treatment of HIV infection in adults and children.
Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI). [1] Unlike agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine. [4] Etravirine is marketed by Janssen, a subsidiary of Johnson & Johnson.
Nevirapine was the first NNRTI approved by the U.S. Food and Drug Administration (FDA). It was approved June 21, 1996 for adults and September 11, 1998, for children. It was approved June 21, 1996 for adults and September 11, 1998, for children.
Escitalopram, a selective serotonin reuptake inhibitor (SSRI) used as an antidepressant.. Reuptake inhibitors (RIs) are a type of reuptake modulators.It is a drug that inhibits the plasmalemmal transporter-mediated reuptake of a neurotransmitter from the synapse into the pre-synaptic neuron.
In some literature articles, the terms "mechanism of action" and "mode of action" are used interchangeably, typically referring to the way in which the drug interacts and produces a medical effect. However, in actuality, a mode of action describes functional or anatomical changes, at the cellular level, resulting from the exposure of a living ...